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See Article, pages 554–563Over the last several years, efforts have been made in patients
with genotypes 2 and 3 chronic hepatitis C (CHC) to assess
whether shortening the duration of therapy with pegylated inter-
feron (PEG-IFN) and ribavirin (RBV) might preserve the efﬁcacy of
the standard 24 week treatment duration while decreasing side-
effects and improving tolerability. Data on viral kinetics have
shown that both the effectiveness of IFN in blocking production
of the virus in the ﬁrst phase of viral decline (rapid decline)
and the rate of decline in the second phase (slower decline) differ
in patients with hepatitis C virus (HCV) genotype 1 and in those
with genotypes 2 or 3 [1,2]. This led several investigators to the
hypothesis that in patients with CHC genotype 2 or 3 and rapid
virologic response (RVR, i.e. HCV RNA undetectable after 4 weeks
of therapy), 12–16 weeks of treatment with PEG-IFN and RBV
may be as effective as a course of 24 weeks [3,4], which induces
sustained virologic response (SVR) in about 80% of patients [5,6].
While several European studies [3,7–9] and a study from
Taiwan [10] appeared to support this hypothesis, the results were
somewhat different in the ACCELERATE [11] and NORTH-C [12]
trials. The conﬂicting results may have been due to differences
in the study design, prevalence of advanced ﬁbrosis and cirrhosis,
baseline viral counts, predominant genotype, ethnic background
of the study population, and different RBV dosing schedules.
The earlier trials by Dalgard et al. [7] and VonWagner et al. [8]
included a relatively young HCV population with mostly early-
stage ﬁbrosis, while almost 25% of patients in ACCELERATE (a
large prospective randomized, multinational non-inferiority trial)
had bridging ﬁbrosis or cirrhosis [11]. The absence of bridging
ﬁbrosis/cirrhosis was shown to be an independent predictor of
SVR among genotype 2 and 3 patients by both Dalgard et al. [7]
and Shiffman et al. [11], although this has not been reported by
others [3,8,13].
Unlike most prior studies which evaluated truncation of treat-
ment duration to less than 24 weeks in genotype 2 and 3 patients,
ACCELERATE used a ﬁxed dose RBV (800 mg/d). Since the mean
body weight of ACCELERATE patients with genotype 2, for exam-
ple, was about 84 kg [11], that resulted in a mean daily doseJournal of Hepatology 20
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genotype 2 patients by Yu et al. (mean body weight about
66 kg) [10]. Although Hadziyannis et al. [14] previously showed
that a combination of PEG-IFN alfa-2a and RBV 800 mg/d
was as effective as a combination of PEG-IFN alfa-2a and RBV
1000–1200 mg/d in patients with genotypes 2 and 3 using a
24-week treatment regimen, the prevailing literature as of the
publication of the ACCELERATE study left open the question of
whether a higher weight-based dose of RBV might still permit a
shorter-duration of treatment of genotype 2 and 3 patients with
RVR without increasing the risk of relapse.
The notion that the impairment in SVR with truncated therapy
in RVR patients in ACCELERATE was due to the low, ﬂat RBV dose
(800 mg daily) used in that study was challenged by results of the
NORTH-C trial [12]. Using PEG-IFN alfa-2b 1.5 ug/kg/wk and RBV
800–1400 mg daily in patients (n = 298) with genotype 2 and 3,
the authors were unable to show non-inferiority of the 14-week
regimen (as compared to a 24-week regimen) in patients with
RVR, with lower SVR (81% vs. 91%) and higher relapse rates
(11% vs. 5%) in those treated for 14 weeks. Despite the inferiority
of the 14-week regimen, Dalgard et al. suggested that a 26–32%
reduction of drug exposure and cost with 14 weeks of treatment
in patients with RVR – recognizing that this would entail a 24-
week course of retreatment for the minority with relapse – justi-
ﬁed truncation of therapy in such patients (as long as the relapse
rate is less than 35%) [12].
Given the intense motivation among most physicians and
patients to optimize the chance of success with the initial course
of therapy for CHC, the non-uniformity of the data on truncation
of therapy in patients with genotypes 2 and 3 who attain RVR has
led many clinicians to continue to treat these patients for
24 weeks. The study by Manns et al. [15], as reported in the cur-
rent issue of the Journal, provides the opportunity to glean fur-
ther insights into this question, along with other aspects of
therapy for patients with genotypes 2 and 3, within the context
of a large study evaluating both a lower dose of PEG-IFN alfa-
2b and a reduced treatment duration. In this study, treatment-
naïve patients with CHC genotype 2 and 3 infection were derived
from two cohorts: the Hep-Net cohort enrolled in Germany and
an international cohort enrolled throughout Europe and Asia.
Patients were randomized to receive PEG-IFN alfa-2b (1.5 lg/
kg/wk) for 24 weeks (group A), PEG-IFN alfa-2b (1.0 lg/kg/wk)11 vol. 55 j 505–506
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for 24 weeks (group B) or PEG-IFN alfa-2b (1.5 lg/kg/wk) for
16 weeks (group C); all in combination with weight-based RBV
(800–1200 mg/day). Treatment duration in group C, as well as
in groups A and B, was independent of RVR; patients were not
randomized to 16 vs. 24 weeks of therapy based on RVR. More-
over, data on week 4 HCV RNA were assessed only in the Interna-
tional cohort.
Of the 682 patients enrolled in the study 80% were of geno-
type 3, which potentially constrains the ability to draw compara-
bly robust conclusions about both of the evaluated genotypes.
SVR rates were 66.5%, 64.3%, and 56.6% for groups A, B, and C,
respectively, with groups B and C failing to show non-inferiority
relative to group A. Relapse rates were 17.8%, 16.3%, and 29.3%,
respectively. Among those who achieved an RVR in the Interna-
tional cohort, SVR rates were consistently high across all treat-
ment arms: 75.3%, 75.9%, and 72.4%, respectively. The relapse
rates in the RVR patients were not provided. Among genotype 3
patients, SVR was similar in groups A and B but lower in group
C. While in group A SVR rates were highest in patients with geno-
type 2 infection and low baseline viral load, even among geno-
type 2 patients with low baseline viral load, SVR rates were
lower in group C compared with group A. Treatment-related seri-
ous adverse events were highest in group A and predictably,
lowest in group C. However, adverse events leading to discontin-
uation of therapy were similar across the arms.
The current study by Manns et al. [15] adds support to the
growing body of literature, including two recent meta-analyses
[16,17], suggesting that 24 weeks of therapy should remain the
standard of care for genotype 2 and 3 patients. It does demon-
strate, however, that the dose of Peg-IFN alfa-2b can be reduced
to 1.0 lg/kg/wk in those with safety concerns without substantial
decline in efﬁcacy. It reafﬁrms that genotype 3 patients should
not be treated routinely for less than 24 weeks, as well as those
patients with either genotype 2 and 3 without RVR. It again
brings up the question whether, based on the low SVR rate of
about 50% in these non-RVR populations, treatment of over
24 weeks duration might be indicated and randomized controlled
trials, such as one currently in progress, are needed to address
that issue.
While supporting 24 weeks as the overall standard of care,
Manns et al. lend credence to the concept of truncation of therapy
in patients with genotype 2 or 3 who achieve an RVR with
weight-based ribavirin. The data in the overall literature, how-
ever, remain inconclusive as to whether this can be done rou-
tinely without jeopardizing the chance of SVR to any signiﬁcant
extent even among ‘‘favorable’’ patient populations with charac-
teristics such as younger age [7,10,11,18], no or minimal ﬁbrosis
[7,9,11,19], BMI 630 kg/m2 [11,19,20], low viral load [7–9,11,19],
genotype 2 [8,11], or platelet countP140,000 [20]. Despite the
potential merit of a cost-effectiveness argument in support of
shorter treatment, or a modest improvement in tolerability,
many clinicians would ﬁnd it problematic to routinely administer
a regimen that had failed to demonstrate non-inferiority to
patients who wish to maximize their prospects of success during
the initial treatment course without incurring any incremental
chance of having to undergo a repeat therapy. Based on the avail-
able data, truncated therapy with PEG-IFN and RBV should be
reserved – after individualized discussion about beneﬁt-risk
considerations – for genotype 2 or 3 patients with favorable
treatment characteristics who have attained RVR if they have
signiﬁcant tolerability issues after 12–16 weeks of therapy.506 Journal of Hepatology 201Conﬂict of interest
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